Table 1 Summary of positive phase 3 clinical trials of angiogenic inhibitors in patients with advanced hepatocellular carcinoma (HCC)
Molecules | Trial | N | Population | mOS | mPFS | ORR | DCR | Comments |
|---|---|---|---|---|---|---|---|---|
Sorafenib | SHARP [18] | 602 | First-line Versus placebo | 10.7 m | 5.5 m | 2% | 43% |  |
|  | ASIAPACIFIC [19] | 226 | First-line Versus placebo | 6.5 m | 2.8 m | 3.3% | 35.3% |  |
Lenvatinib | REFLECT [20] | 954 | First-line Versus sorafenib | 13.6 m | 8.9 m | 24.1, 1%CR | 75.5% |  |
Regorafenib | RESORCE [21] | 573 | Second-line Versus placebo | 10.6 m | 3.2 m | 11% | 65% | Exclusion of patients previously intolerant to sorafenib |
Cabozantinib | CELESTIAL [22] | 707 | Second or third-line Versus placebo | 10.2 m | 5.2 m | 4% | 64% | Inclusion of patients previously intolerant to sorafenib |
Ramucirumab | REACH-2 (35) | 292 | Second-line Versus placebo | 8.5 m | 2.8 m | 4.6% | 59.9% | Inclusion of patients with poor prognosis based on high alpha-foeto-protein levels |